{"name":"Roivant Sciences Ltd.","slug":"roivant","ticker":"ROIV","exchange":"NASDAQ","domain":"roivant.com","description":"Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.","hq":"Basel, Switzerland / New York, NY","founded":0,"employees":"750","ceo":"Matt Gline","sector":"Diversified Biotech / Holding Company","stockPrice":29.34,"stockChange":0.12,"stockChangePercent":0.41,"marketCap":"$21.0B","metrics":{"revenue":29053000,"revenueGrowth":-77.8,"grossMargin":0,"rdSpend":550413000,"netIncome":-171981000,"cash":4529977856,"dividendYield":0,"peRatio":-25.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Ubrogepant patent cliff ($1.4B at risk)","drug":"Ubrogepant","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Tapinarof patent cliff ($500M at risk)","drug":"Tapinarof","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Roivant Sciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Roivant Sciences reported its financial results for the fourth quarter and full year 2023, with revenue of $1.4 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Roivant Sciences Announces Collaboration with Biogen to Develop and Commercialize Novel Therapies","summary":"Roivant Sciences announced a collaboration with Biogen to develop and commercialize novel therapies for neurological disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNVWQza3V1VkkyVmJuZ1plUHdWQ1RNMkJ4eXprTkRVVnFmVXRGdDdDSzNWSExXUkZfam9QcXBic1FKc0lHazVoRnR5Y3l5TERRSHEtd2IyM29SamxtTXdkVnBJZ1VZTmZ0NHc1a3FyRUNDRVc4MDBfVGpsbG9RQ3ZleXlkc2thODQwYXNmeC0zMHlMZG01WC1MdlZqM3JMaWMtVnMtdWRscmkxN1JiaW4xMld1dXI?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares - Stock Titan","headline":"Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOOWlscEZ3YmFXUm5pUFRIWTUwNDJYRFNkS05zaDRrV2xTS0w5TWwwcWpwNU5oOG5zM21SaFQyR1NjQW9xa0JyTzRXeG9Kd25CSjFsWU1sSG9heTY3MVMxMDJMdi02V0JVS3JYVGprc2tYWm11ZnEzci0xT2IweUpVQXQwYzRPV1RnVktGOUJfcThtWnBCbUM3UjV0S0s0LVk?oc=5","date":"2026-03-04","type":"patent","source":"bioworld.com","summary":"Moderna to pay up to $2.25B to settle COVID-19 patents case - bioworld.com","headline":"Moderna to pay up to $2.25B to settle COVID-19 patents case","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOcE5wTndjTDBpNEpmeHhzSWJvUDkzeHR1Zk9kNE9MSWpWMF9CYW81MUp3bFhFem1YOFIyY0NzQWhveGF0YWpGX2F4QjFuaV9NQ2lsTWRuQVdLXzZYeEZtenItMTBHcUx6ZkhIX2hpQ1Z2Yk85NEp3M2NXal9XX0ZxaW8xakQxQ1hrVWhOSTJENWpOWWxDZnRSQXNSWGdSX19nekd3?oc=5","date":"2026-02-07","type":"trial","source":"TechStock²","summary":"Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²","headline":"Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQODhkbmkxMEhHc1VmbURzc1NuOUUzZm0wbjFrdXFNWUlieG5SSmJ2cFFnTUpFblVKcnEtd1BJV2tFZmd1S0pFWkx2NzhWN1UzQnhiLU5kamhsUHh2Q2RfeVpxQ3A3R25RbF8zeS15WHM2NzFHYjViblotLXIxZG1JanBZM0hiY0FzaDhLN1Y5SENUX0pQR3ptNW9RYTYwSEUwQ1JtcmY3eGVod1lCNi1Kbkc1X0hKdU9GVkRaTUx4aVNOT29Ma0NoQjNRSlMtbUtEbG53UzJn?oc=5","date":"2026-01-20","type":"deal","source":"Sahm","summary":"Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Sahm","headline":"Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"simplywall.st","summary":"High Growth Tech Stocks In The US For January 2026 - simplywall.st","headline":"High Growth Tech Stocks In The US For January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNSXBQR0Q3YkJnZkF3ck1Md2VjRFJWRjR4eDM4Z1Mwb0NRNTVkQ3pHSnlhZlRQM2R4d2Jkd1hpY0VYZDZSS3BJWXRULW5iMjJKQWI2N29JUk81MjljSTNmZlM0Q0JvTS1wY0JDMkZlRXVQbEZUT0Z2NGtlUjhpTk13S05sVXNEcjJQZi0w?oc=5","date":"2025-11-17","type":"pipeline","source":"InvestorPlace","summary":"Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace","headline":"Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQbXlzeGxCYkllcUhMdGZJSkZ2RjluMXRoVzB1N0s3WkU4QzZFZEJXUWh5cnRfLU1Nc3ozdV8zb25ldDdwVDBwREV2MWJnc0dCZjRmcTMxTUZYdzVRRERKY0tHWG5nRkYyT05sYW0wWTNIdFNPb0JYQXdsVEtFQ3Jyc2xvXzBSVGdZVDNUY01rTmd6dFpVX1J6VWFsaHI5STJHRHc?oc=5","date":"2025-11-13","type":"pipeline","source":"Seeking Alpha","summary":"Roivant Sciences: Brepocitinib And Roadmap Still Underpriced (NASDAQ:ROIV) - Seeking Alpha","headline":"Roivant Sciences: Brepocitinib And Roadmap Still Underpriced (NASDAQ:ROIV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQV0JVd3kzZ2kyRXRDLUl3UkJreVdBYzB4cGdDRDBweFEtLVp4SWRNa0d6RmFGaV9rRno5a29sQV9LRy1fZExqbUxRWlJkZl9uLXhKczFwT3J6SjV0OFRRdnlzYXZGRHRDZTEwRVFQZjBHODRxaWhSVGFXaUhRYjBqYlVpdXlqeGJIYzZaRGhNRlY?oc=5","date":"2025-11-04","type":"pipeline","source":"Yahoo Finance","summary":"Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - Yahoo Finance","headline":"Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE43M1U3bXZWQk5LWlhqWllnc3RXUDU5LWV0QzdmVGRpd1lDUlNPMklZZDVmeU1MNVFER1VYZnl2QVlNVmQ5MnlPWjdRMzE5cHViTTJlS05jRzFTQVpGREt1OTY4dnVJNmhuaVJSUk9zYW9xUQ?oc=5","date":"2025-09-24","type":"pipeline","source":"TIKR.com","summary":"SPDR S&P Biotech ETF (XBI) Top 25 Holdings - TIKR.com","headline":"SPDR S&P Biotech ETF (XBI) Top 25 Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNa1l2cFA5bFhDbWpxOWxzcDVfcTdXYXVRdjJ1UWYwYUN2cTBLR2pXcWNqQmpJUzVGTmxuZWFPNzRJRm85Q0dRVDF4bXRqQm4tMU5jVldtWXU5RmJUYjBsUkZiNlRLTi10R19wS1JRSGwxMWdCUjhKN3RZTkhXSUZGS1F1V0k4UVVsTHB4MWh0OERxTUlYUmVNODZPbDk4eTRLY3RlX3QzMVJCLUtIQWw5ZkFXb2k0N3VnVG9NeWE3SFlTQQ?oc=5","date":"2025-07-05","type":"earnings","source":"Seeking Alpha","summary":"Roivant Stock: Booming Pipeline Without Product Revenues Creates Valuation Riddle (ROIV) - Seeking Alpha","headline":"Roivant Stock: Booming Pipeline Without Product Revenues Creates Valuation Riddle (ROIV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPUW84SmFsSEhsbGFWRVd2a2pRWTFWcl9FV29lUDZwWV9uVm5JSngxREJLUjJUdGQ0SVJmQ0tIamdYX1FQYWRLNmpPTUF0VXY2bkI4WGdNUUYwQmFNcDhZWXgtT2lTNHhCRHJmTzhlNG9YUnk2VDhCOGdYbG5hb1Nxdzg5VzVaYWNLd25BYkF4N2RmSE9xOWJpakFCejlzd2ZEcjBEMVluTTRMZ1ktd29qcG1IUXRtWnRjdkR3TXNDYXo3N2JZOGlsYUYtVWgtd0Z3LVpYOA?oc=5","date":"2025-01-15","type":"pipeline","source":"Investing.com","summary":"Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com","headline":"Roivant sciences increases stake in Immunovant with $336.9 million purchase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNVHoydVlJbFJNdE1sNm1USWFCZnlqR0VMTGtrZGZiUkJFN1pSTDUyUWxJTVJyc3Q5Q2xwY1pNTVpuUS1udHl4QVlzeFZ6V3pWd3NlY2duejZwcmViVC1nSUdPX3ZDNEpSSWJ0cGhvYmVhOUIybUlscy1jb25VY3h2UjhKWEZoeW52bzRMOEpPS2Q1b3hiZjR3VGs5bFp4ZllQWlB1cTBjRE54R3MxdTQ0ODRn?oc=5","date":"2024-09-10","type":"deal","source":"BioCentury","summary":"Deals report: Roivant sets up Pulmovant to advance hypertension therapy - BioCentury","headline":"Deals report: Roivant sets up Pulmovant to advance hypertension therapy","sentiment":"neutral"}],"patents":[{"drugName":"Ubrogepant","drugSlug":"ubrogepant","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Tapinarof","drugSlug":"tapinarof","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Eli Lilly","GSK"],"therapeuticFocus":["Psychiatry","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":29053000,"revenuePeriod":"2025-03-31","revenueHistory":[{"value":29053000,"period":"2025-03-31"},{"value":124795000,"period":"2024-03-31"},{"value":32713000,"period":"2024-03-31"},{"value":61280000,"period":"2023-03-31"},{"value":61280000,"period":"2023-03-31"}],"grossProfit":28142000,"grossProfitHistory":[{"period":"2025-03-31","value":28142000},{"period":"2024-03-31","value":31114000},{"period":"2023-03-31","value":28496000},{"period":"2022-03-31","value":46320000}],"rdSpend":550413000,"rdSpendHistory":[{"period":"2025-03-31","value":550413000},{"period":"2024-03-31","value":439909000},{"period":"2023-03-31","value":454062000},{"period":"2022-03-31","value":483035000}],"sgaSpend":591410000,"operatingIncome":-1113681000,"operatingIncomeHistory":[{"period":"2025-03-31","value":-1113681000},{"period":"2024-03-31","value":-824928000},{"period":"2023-03-31","value":-809014000},{"period":"2022-03-31","value":-1211748000}],"netIncome":-171981000,"netIncomeHistory":[{"period":"2025-03-31","value":-171981000},{"period":"2024-03-31","value":4348926000},{"period":"2023-03-31","value":-1009030000},{"period":"2022-03-31","value":-845262000}],"eps":-0.24,"epsHistory":[{"period":"2025-03-31","value":-0.24},{"period":"2024-03-31","value":5.23},{"period":"2023-03-31","value":-1.42},{"period":"2022-03-31","value":-1.26}],"cash":2715411000,"cashHistory":[{"period":"2025-03-31","value":2715411000},{"period":"2024-03-31","value":6494953000},{"period":"2023-03-31","value":1676813000},{"period":"2022-03-31","value":2060400000}],"totalAssets":5436940000,"totalLiabilities":249742000,"totalDebt":100170000,"equity":4687605000,"operatingCashflow":-839451000,"operatingCashflowHistory":[{"period":"2025-03-31","value":-839451000},{"period":"2024-03-31","value":-765268000},{"period":"2023-03-31","value":-843393000},{"period":"2022-03-31","value":-677729000}],"capex":-4599000,"capexHistory":[{"period":"2025-03-31","value":-4599000},{"period":"2024-03-31","value":-1382000},{"period":"2023-03-31","value":-12690000},{"period":"2022-03-31","value":-17436000}],"freeCashflow":-844050000,"dividendsPaid":null,"buybacks":-1293232000,"employees":750,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":175072000,"ebit":-339153000,"ebitda":-338462000,"period":"2025-12-31","revenue":1999000,"epsBasic":-0.38,"netIncome":-265891000,"rdExpense":165380000,"epsDiluted":-0.381556,"grossProfit":1299000,"operatingIncome":-339153000},{"sga":143125000,"ebit":-306233000,"ebitda":-305312000,"period":"2025-09-30","revenue":1571000,"epsBasic":-0.17,"netIncome":-113519000,"rdExpense":164568000,"epsDiluted":-0.17,"grossProfit":1460000,"operatingIncome":-306233000},{"sga":134019000,"ebit":-284922000,"ebitda":-283824000,"period":"2025-06-30","revenue":2170000,"epsBasic":-0.33,"netIncome":-223355000,"rdExpense":152919000,"epsDiluted":-0.33,"grossProfit":2016000,"operatingIncome":-284922000},{"sga":147092000,"ebit":-284965000,"ebitda":-283540000,"period":"2025-03-31","revenue":7570000,"epsBasic":-0.29,"netIncome":-206475000,"rdExpense":145238000,"epsDiluted":-0.29,"grossProfit":7365000,"operatingIncome":-284965000},{"sga":141545000,"ebit":-274381000,"ebitda":-271460000,"period":"2024-12-31","revenue":9018000,"epsBasic":0.23,"netIncome":169381000,"rdExpense":141595000,"epsDiluted":0.23,"grossProfit":8759000,"operatingIncome":-274381000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":29.34,"previousClose":29.22,"fiftyTwoWeekHigh":30.33,"fiftyTwoWeekLow":10.58,"fiftyTwoWeekRange":"10.58 - 30.33","fiftyDayAverage":28.38,"twoHundredDayAverage":21.31,"beta":1.14,"enterpriseValue":17196718080,"forwardPE":-25.3,"priceToBook":4.88,"priceToSales":1577.66,"enterpriseToRevenue":1292.02,"enterpriseToEbitda":-13.6,"pegRatio":0,"ebitda":-1264381952,"ebitdaMargin":0,"freeCashflow":-334342944,"operatingCashflow":-759096000,"totalDebt":108939000,"debtToEquity":2.2,"currentRatio":30.66,"returnOnAssets":-14.5,"returnOnEquity":-19.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":12,"targetMeanPrice":35.67,"targetHighPrice":41,"targetLowPrice":29,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":22.8,"institutionHeldPercent":74.2,"sharesOutstanding":715701137,"floatShares":542021942,"sharesShort":27055375,"shortRatio":5.37,"shortPercentOfFloat":3.8,"epsTrailing":-1.17,"epsForward":-1.16,"revenuePerShare":0.02,"bookValue":6.02,"officers":[{"age":41,"name":"Mr. Matthew  Gline","title":"CEO & Director"},{"age":38,"name":"Dr. Eric  Venker M.D., Pharm.D.","title":"President & CEO of Immunovant"},{"age":49,"name":"Dr. Mayukh  Sukhatme M.D.","title":"President, Chief Investment Officer & Director"},{"age":45,"name":"Mr. Richard  Pulik","title":"Chief Financial Officer"},{"age":44,"name":"Ms. Jennifer  Humes","title":"Chief Accounting Officer"},{"age":46,"name":"Dr. Frank M. Torti M.B.A., M.D.","title":"President & Vant Chair"},{"age":null,"name":"Dr. Huafeng  Xu Ph.D.","title":"Chief Technology Officer"},{"age":null,"name":"Mr. Ian  Rosenblum","title":"Chief Information Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://roivant.com","phone":"44 20 7400 3347"}}